Loading...
Loading...
Available on 1 platform
Sign in to view source links and access this dataset
77 patients with hematological malignancies receiving active treatment were compared to matched healthy controls for humoral and cellular vaccine responses. Seroconversion occurred in only 8% and 21% of patients after the first and second vaccine dose, versus 93% and 100% of controls. The dataset, authored by Lucia Mazzotti and last updated in May 2026, includes measurements of Spike-specific IgG titers, T-cell ELISpot assays, and T-cell receptor repertoire sequencing from baseline to six months post-vaccination.
Primary data file is in DOCX format, which may require conversion for analysis.